Effect of Pyunkang-tang on Inflammatory Aspects of Chronic Obstructive Pulmonary Disease in a Rat Model

Seo, Hyo-Seok; Lee, Hyun Jae; Lee, Choong Jae

doi:10.20307/nps.2019.25.2.103

Cited by 4 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the research object, the inclusion criteria were set as follows: ① the patients met the diagnostic criteria of COPD in GOLD Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2021) [ 10 ] and diagnostic criteria of TCM Syndromes in Chronic Obstructive Pulmonary Disease (2011) [ 11 ]; ② the patients were in stable period; ③ according to the severity of COPD graded by FEV1/FVC, patients with an FEV1/FVC level of 30–70% were included, and the very severe patients were excluded; ④ the patients had no contraindication for tiotropium, and they were over 18 years old; ⑤ the patients and their families were informed of this study and signed the informed consent. Exclusion criteria were set as follows: ① the patients had a history of taking glucocorticoids and bronchodilator agents for a long time; ② the patients' pulmonary disease was caused by pulmonary tuberculosis, tumor, bronchial dilation, and other factors; ③ the patients were complicated with severe and unstable organic dysfunction; ④ the patients' treatment compliance was poor or their clinical data were incomplete; ⑤ the patients could not state their chief complaint clearly.…”

Section: Methodsmentioning

confidence: 99%

Effect of Yifei-Huoxue Decoction Combined with Tiotropium on Inflammatory Cytokine Levels, Pulmonary Function, and Quality of Life in Patients with Chronic Obstructive Pulmonary Disease

Sheng

Feng³

2022

Computational Intelligence and Neuroscience

View full text Add to dashboard Cite

Objective. The main objective is to investigate the effect of Yifei-Huoxue decoction combined with tiotropium on the inflammatory cytokine levels, pulmonary function, and quality of life in patients with chronic obstructive pulmonary disease (COPD). Methods. Ninety-eight COPD patients who were treated in our hospital from January 2021 to January 2022 were selected as the research objects, and they were divided into reference group (routine treatment) and study group (Yifei-Huoxue decoction combined with tiotropium), with 49 cases in each group. The patients’ clinical indexes were compared between the two groups, and the clinical efficacy in the two groups was analyzed. Results. Compared with the reference group, the study group had remarkably lower inflammatory cytokine levels (including tumor necrosis factor- α (TNF- α ), C-reactive protein (CRP), and interleukin-6 (IL-6)) after treatment P > 0.05 . In terms of the patients’ pulmonary function indexes after treatment, the study group achieved lower forced vital capacity (FVC), forced expiratory volume in 1s (FEV1), and FEV1/FVC levels compared with the reference group P < 0.05 . Both groups had a lower erythrocyte sedimentation rate (ESR) after treatment compared with that before treatment. However, the intergroup difference in the ESRs after treatment was remarkable, and the study group had a much lower ESR compared with the reference group (P < 0.05). Compared with the reference group, the study group achieved much higher 36-item short form health survey (SF-36) scores in dimensions of general health, physical functioning, social functioning, and mental health after treatment (P < 0.05). Conclusion. Yifei-Huoxue decoction combined with tiotropium not only enhances the COPD patients’ pulmonary function but also decreases their inflammatory levels. Therefore, this treatment is conducive to promoting the COPD patients’ recovery and exerts positive effect on improving their quality of life.

show abstract

Section: Methodsmentioning

confidence: 99%

Effect of Yifei-Huoxue Decoction Combined with Tiotropium on Inflammatory Cytokine Levels, Pulmonary Function, and Quality of Life in Patients with Chronic Obstructive Pulmonary Disease

Sheng

Feng³

2022

Computational Intelligence and Neuroscience

View full text Add to dashboard Cite

show abstract

“…Hematological tests: complete blood count, differential count (neutrophils, eosinophils, basophils, lymphocytes, monocytes), erythrocyte sedimentation rate; Blood chemistry tests: aspartate aminotransferase, alanine aminotransferase, γ-glutamyl transferase, alkaline phosphatase, blood urea nitrogen, creatinine, total bilirubin, uric acid, total protein, albumin, glucose, and estimated glomerular filtration rate; Urine tests: pH, albumin, glucose, ketone, blood, urobilinogen, bilirubin, nitrite, leukocytes, and specific gravity. 8 , monitor compliance using the E-diary and reconfirm at each visit. If study subject has difficulty using a smartphone or computer, the investigator asks the subject to write daily records of dietary and life habits, and checks them at each visit.…”

Section: Eligibility Criteriamentioning

confidence: 99%

“…It also reduces tissue eosinophilia and bronchial hyperresponsiveness, which suggests that it may play a positive role in patients with respiratory symptoms of airway disease (7). In a study that used an animal model of chronic obstructive pulmonary disease (COPD), RAE inhibited cigarette smoke-induced pulmonary inflammation and mucin hypersecretion (8). R h i z o m a d i o s c o r e a e e x t r a c t ( R D E ) p r o d u c e s immunomodulatory effects by inhibiting pro-inflammatory cytokines (9,10).…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of HX 110-A and HX 110-B in promoting respiratory health: protocol for an 8-week, randomized, double-blind, parallel group, placebo-controlled trial

Lee

et al. 2020

Ann Palliat Med

View full text Add to dashboard Cite

Background: HX110-A and HX110-B are compound extracts based on radix adenophorae and rhizoma dioscoreae, respectively, which have anti-inflammatory activity. There are limited data on whether they may help improve respiratory conditions including lung function. Therefore, in this trial, we will evaluate the effectiveness and safety of the use of HX110-A and HX110-B for the treatment of respiratory health in adults with mild respiratory symptoms.Methods: This will be an 8-week, randomized, double-blind, parallel group, placebo-controlled trial with three arms. Adults more than 40 years old with persistent respiratory symptoms will be enrolled. Patients with definite respiratory disease or with a history of recent intake of antioxidants or anti-inflammatory agents will be excluded. Study subjects will be assigned at a 1:1:1 ratio into the following three arms: controls, experimental group 1 (HX110-A), and experimental group 2 (HX110-B). Control or experimental foods will be administered for 8 weeks, and follow-up will be up to 12 weeks. The primary outcome will be total antioxidant capacity. Secondary outcomes will be inflammatory indexes, respiratory symptoms, lung function, quality of life, and fatigue level. Safety outcomes will be assessed by monitoring adverse events and vital signs, and through clinical pathology tests.Discussion: This trial will reveal the effectiveness and safety of HX110-A and/or HX110-B for medical purposes in adults with respiratory symptoms. The results should clarify if active intake of specific foods with these functional compounds may promote respiratory health in adults without definite respiratory disease.

show abstract

“…It also reduces tissue eosinophilia and bronchial hyperresponsiveness, which suggests that it may play a positive role in patients with respiratory symptoms of airway disease [7]. In a study that used an animal model of chronic obstructive pulmonary disease (COPD), RAE inhibited cigarette smoke-induced pulmonary inflammation and mucin hypersecretion [8]. Rhizoma dioscoreae extract (RDE) produces immunomodulatory effects by inhibiting pro-inflammatory cytokines [9,10].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of HX 110-A and HX 110-B in promoting respiratory health: An 8-week, randomized, double-blind, parallel group, placebo-controlled trial

Lee

Yoon

et al. 2020

Preprint

View full text Add to dashboard Cite

Background HX110-A and HX110-B are compound extracts based on radix adenophorae and rhizoma dioscoreae, respectively, which have anti-inflammatory activity. There are limited data on whether they may help improve respiratory conditions including lung function. Therefore, in this trial, we will evaluate the effectiveness and safety of the use of HX110-A and HX110-B for the treatment of respiratory health in adults with mild respiratory symptoms. Methods/design This will be an 8-week, randomized, double-blind, parallel group, placebo-controlled trial with three arms. Adults more than 40 years old with persistent respiratory symptoms will be enrolled. Patients with definite respiratory disease or with a history of recent intake of antioxidants or anti-inflammatory agents will be excluded. Study subjects will be assigned at a 1:1:1 ratio into the following three arms: controls, experimental group 1 (HX110-A), and experimental group 2 (HX110-B). Control or experimental foods will be administered for 8 weeks, and follow-up will be up to 12 weeks. The primary outcome will be total antioxidant capacity. Secondary outcomes will be inflammatory indexes, respiratory symptoms, lung function, quality of life, and fatigue level. Safety outcomes will be assessed by monitoring adverse events and vital signs, and through clinical pathology tests. Conclusion We hope that this trial will reveal the effectiveness and safety of HX110-A and/or HX110-B for medical purposes in adults with respiratory symptoms. The results should clarify if active intake of specific foods with these functional compounds may promote respiratory health in adults without definite respiratory disease.

show abstract

Effect of Pyunkang-tang on Inflammatory Aspects of Chronic Obstructive Pulmonary Disease in a Rat Model

Cited by 4 publications

References 25 publications

Effect of Yifei-Huoxue Decoction Combined with Tiotropium on Inflammatory Cytokine Levels, Pulmonary Function, and Quality of Life in Patients with Chronic Obstructive Pulmonary Disease

Effect of Yifei-Huoxue Decoction Combined with Tiotropium on Inflammatory Cytokine Levels, Pulmonary Function, and Quality of Life in Patients with Chronic Obstructive Pulmonary Disease

Efficacy and safety of HX 110-A and HX 110-B in promoting respiratory health: protocol for an 8-week, randomized, double-blind, parallel group, placebo-controlled trial

Efficacy and safety of HX 110-A and HX 110-B in promoting respiratory health: An 8-week, randomized, double-blind, parallel group, placebo-controlled trial

Contact Info

Product

Resources

About